Literature DB >> 30702394

Focal arm weakness following intradetrusor botulinum toxin administration in spinal cord injury: Report of two cases.

Christopher Goodrich1, Henry York2,3, Andrew Shapiro4, Peter Howard Gorman2,3.   

Abstract

Context: Outpatient Spinal Cord Injury follow-up practice Findings: We present two cases of individuals with tetraplegia who experienced proximal arm weakness temporally related to the administration of intradetrusor onabotulinumtoxinA without other systemic effects. This arm weakness lasted approximately three months in both cases, whereas the effect of the toxin on the bladder lasted for over six months. In one of the cases, the pattern of proximal arm weakness after intravesicular botulinum toxin injection recurred after repeat injection.
Conclusion: These cases represent a previously unreported phenomenon of proximal focal weakness associated with the use of intradetrusor chemodenervation. Possible mechanisms for these cases are discussed.

Entities:  

Keywords:  Arm weakness; Botulinum toxin; Chemodenervation; Detrusor overactivity; Neurogenic bladder

Year:  2019        PMID: 30702394      PMCID: PMC7801024          DOI: 10.1080/10790268.2018.1464693

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  17 in total

Review 1.  Adverse events after botulinum A toxin injection for neurogenic voiding disorders.

Authors:  K De Laet; J-J Wyndaele
Journal:  Spinal Cord       Date:  2005-07       Impact factor: 2.772

2.  Botulinum toxin--new mechanisms, new therapeutic directions?

Authors:  Christopher Chapple; Anand Patel
Journal:  Eur Urol       Date:  2006-01-20       Impact factor: 20.096

Review 3.  Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke.

Authors:  Andrea Santamato; Maria Francesca Micello; Maurizio Ranieri; Giovanni Valeno; Antonio Albano; Alessio Baricich; Carlo Cisari; Domenico Intiso; Alberto Pilotto; Giancarlo Logroscino; Francesco Panza
Journal:  J Neurol Sci       Date:  2015-02-07       Impact factor: 3.181

4.  Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury.

Authors:  Prasad S Patki; Rizwan Hamid; Kirupakar Arumugam; P Julian R Shah; Mike Craggs
Journal:  BJU Int       Date:  2006-07       Impact factor: 5.588

Review 5.  Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature.

Authors:  Beth E Crowner; Diego Torres-Russotto; Alexandre R Carter; Brad A Racette
Journal:  Clin Neuropharmacol       Date:  2010 Sep-Oct       Impact factor: 1.592

6.  Contralateral weakness following botulinum toxin for poststroke spasticity.

Authors:  Anila M Thomas; David M Simpson
Journal:  Muscle Nerve       Date:  2012-09       Impact factor: 3.217

7.  125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection.

Authors:  H Wiegand; G Erdmann; H H Wellhöner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

8.  Distant effects of local injection of botulinum toxin.

Authors:  D J Lange; M F Brin; C L Warner; S Fahn; R E Lovelace
Journal:  Muscle Nerve       Date:  1987 Jul-Aug       Impact factor: 3.217

9.  Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.

Authors:  A Haferkamp; B Schurch; A Reitz; U Krengel; J Grosse; G Kramer; S Schumacher; P J Bastian; R Büttner; S C Müller; M Stöhrer
Journal:  Eur Urol       Date:  2004-12       Impact factor: 20.096

10.  Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.

Authors:  A Apostolidis; R Popat; Y Yiangou; D Cockayne; A P D W Ford; J B Davis; P Dasgupta; C J Fowler; P Anand
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.